咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >A new era in the treatment of ... 收藏

A new era in the treatment of erectile dysfunction

作     者:Padma-Nathan, H 

作者机构:Male Clin Beverly Hills CA 90212 USA 

出 版 物:《AMERICAN JOURNAL OF CARDIOLOGY》 

年 卷 期:1999年第84卷第5B期

页      面:18N-23N页

核心收录:

学科分类:1002[医学-临床医学] 100201[医学-内科学(含:心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

摘      要:The recent introduction of sildenafil has revolutionized the treatment of erectile dysfunction (ED). The availability of sildenafil, the first effective oral agent for ED, has also expanded the field of sexual healthcare to include general and primary care practitioners and other nonurology specialists. A new process-of-care algorithm has been developed to facilitate the evaluation and treatment of ED in these nonurology settings. Sildenafil has been demonstrated to be safe and effective in randomized, double-blind, placebo-controlled trials involving 3,000 men ages 19-87 years. Sildenafil is effective across a broad range of etiologies including diabetes. For patients in whom first-line treatment with sildenafil fails or ceases to be effective, second-line interventions with intracavernosal self-injection therapy or transurethral alprostadil may be indicated. In addition to sildenafil, other oral agents such as oral phentolamine and sublingual apomorphine are now in clinical trials. Drugs under development include second-generation phosphodiesterase type 5 (PDE5) inhibitors, endothelin antagonists, and agents that offer specific molecular targeting. Clinical studies are also being planned to examine the efficacy of combination oral drug regimens for ED. (C) 1999 by Excerpta Medica, Inc.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分